Company: NDRA
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001213900-25-110887
Chunk: 11

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 11
---
 incurred $1,341,859 and $2,552,336 of expenses related to research and development costs, respectively.

Net Earnings (Loss) Per Common Share

The Company computes earnings per share under
ASC Subtopic 260-10, “Earnings Per Share”. Basic earnings (loss) per share is computed by dividing the net income (loss) attributable
to the common stockholders (the numerator) by the weighted average number of shares of common stock outstanding (the denominator) during
the reporting periods. Diluted loss per share is computed by increasing the denominator by the weighted average number of additional shares
that could have been outstanding from securities convertible into common stock (using the “treasury stock” method), unless
their effect on net loss per share is anti-dilutive. There were 328,143 and 180,986 potentially dilutive shares, which include outstanding
common stock options, and warrants, as of September 30, 2025 and December 31, 2024, respectively.

    September 30,  
    December 31, 

    2025  
    2024 
  
    Options to purchase common stock 
     266  
     278 
  
    Warrants to purchase common stock 
     180,707  
     180,707 
  
    Shares issuable upon conversion of Series A Convertible Preferred Stock 
     1  
     1 
  
    Restricted Stock Units 
     147,169  
     - 
  
    Potential equivalent shares excluded 
     328,143  
     180,986 

7

Fair Value Measurements

Disclosures about fair value of financial instruments
require disclosure of the fair value information, whether or not recognized in the balance sheet, where it is practicable to estimate
that value.

In accordance with ASC Topic 820, “Fair
Value Measurements and Disclosures,” the Company measures certain financial instruments at fair value on a recurring basis. ASC
Topic 820 defines fair value, established a framework for measuring fair value in accordance with accounting principles generally accepted
in the United States, and expands disclosures about fair value measurements.

Fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement
date. ASC Topic 820 established a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy
gives the highest priority